Biogen Idec

Biogen’s MS Pill Gains 8 More Years of Patent Protection

Biogen’s MS Pill Gains 8 More Years of Patent Protection

Bloomberg

4 Key Drug Approvals Expected In The Next 30 Days

4 Key Drug Approvals Expected In The Next 30 Days

investors.com

Best And Worst FDA Drug Approval Stocks of 2013

Best And Worst FDA Drug Approval Stocks of 2013

TheStreet.com

Biogen Idec says it filed for FDA approval of longer-lasting treatment for hemophilia A

Biogen Idec says it filed for FDA approval of longer-lasting treatment for hemophilia A

Yahoo/AP

Amgen And The Biosimilar Threat: Lessons From Affymax

Amgen And The Biosimilar Threat: Lessons From Affymax

Seeking Alpha

Biogen Asked in Suit to Return ALS Biosamples to Knopp

Biogen Asked in Suit to Return ALS Biosamples to Knopp

Bloomberg

Bristol-Myers might just make a big deal, WSJ says

Bristol-Myers might just make a big deal, WSJ says

Fierce Pharma

Biogen says FDA starts review of hemophilia B drug

Biogen says FDA starts review of hemophilia B drug

Yahoo/AP

Elan Armed With Biogen Billions Hunts for Deals: Real M&A

Elan Armed With Biogen Billions Hunts for Deals: Real M&A

Bloomberg

4 Biotech Stock Stars Losing Their Luster

4 Biotech Stock Stars Losing Their Luster

TheStreet.com Stockpkr